Klaria Pharma Holding AB has concluded its rights issue, raising SEK 111.1 million before costs. Voluntary subscriptions accounted for 61.4% of the total, while underwriter Vator Securities AB covered the remaining portion. The company will receive approximately SEK 73.8 million in cash after accounting for SEK 37.3 million in debt set-offs.
The final rights issue outcome shows only 61.4% (SEK 90.6m) of the SEK 111.1m issue was taken up voluntarily, with underwriter Vator subscribing SEK 20.5m (13.9%), a clear sign of weak demand. Non-participating shareholders face roughly 43.0% dilution, and only SEK 73.8m of the proceeds is cash. The secured funding partly offsets the negative demand signal.
- ▼ Final rights issue outcome published 12-13 November 2026 with only 61.4% voluntary subscription
- ▼ Underwriter Vator Securities AB forced to subscribe SEK 20.5m under its underwriting commitment
- ▲ The company now has SEK 73.8m in cash proceeds to settle short-term liabilities and fund its commercial strategy
- ▲ Full exercise of the 46,294,165 TO1 warrants could add approximately SEK 27.8m in further proceeds